Details of the Drug Combination

General Information of Drug Combination (ID: DCZF5OG)

Drug Combination Name
obeticholic acid Bezafibrate
Indication
Disease Entry Status REF
Primary Biliary Cholangitis Phase 2 [1]
Component Drugs obeticholic acid   DM3Q1SM Bezafibrate   DMZDCS0
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of obeticholic acid
Disease Entry ICD 11 Status REF
Primary biliary cholangitis DB96.1 Approved [2]
Insomnia 7A00-7A0Z Clinical trial [3]
obeticholic acid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Farnesoid X-activated receptor (FXR) TTS4UGC NR1H4_HUMAN Modulator [2]
------------------------------------------------------------------------------------
obeticholic acid Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Bile acid-CoA thioesterase (BAAT) DERA3OF BAAT_HUMAN Metabolism [9]
------------------------------------------------------------------------------------
obeticholic acid Interacts with 230 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Very long chain fatty acid elongase 7 (ELOVL7) OT89NYVC ELOV7_HUMAN Increases Expression [7]
cTAGE family member 15 (CTAGE15) OTMOMQGH CTGEF_HUMAN Increases Expression [7]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD) OTOMP6TH PK3CD_HUMAN Decreases Expression [7]
Nuclear receptor subfamily 5 group A member 2 (NR5A2) OTXAUJAS NR5A2_HUMAN Decreases Expression [7]
Suppressor of cytokine signaling 2 (SOCS2) OTBPNKJQ SOCS2_HUMAN Decreases Expression [7]
Copper chaperone for superoxide dismutase (CCS) OTXHT3QO CCS_HUMAN Decreases Expression [7]
Ectoderm-neural cortex protein 1 (ENC1) OTJEUB6U ENC1_HUMAN Increases Expression [7]
Dual specificity mitogen-activated protein kinase kinase 7 (MAP2K7) OT1Q40TZ MP2K7_HUMAN Decreases Expression [7]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2) OT5I4Y9K PLCB_HUMAN Decreases Expression [7]
Peroxisomal acyl-coenzyme A oxidase 3 (ACOX3) OTZEPVGF ACOX3_HUMAN Increases Expression [7]
Tapasin (TAPBP) OTL81AVZ TPSN_HUMAN Decreases Expression [7]
Interleukin-1 receptor-associated kinase-like 2 (IRAK2) OT6Y1QZN IRAK2_HUMAN Decreases Expression [7]
Long-chain-fatty-acid--CoA ligase 4 (ACSL4) OTI71MUJ ACSL4_HUMAN Increases Expression [7]
Transcription factor Maf (MAF) OT1GR3IZ MAF_HUMAN Increases Expression [7]
Ribosomal protein S6 kinase alpha-5 (RPS6KA5) OTAVZJ3J KS6A5_HUMAN Decreases Expression [7]
Ribosomal protein S6 kinase alpha-4 (RPS6KA4) OTTK8MUO KS6A4_HUMAN Decreases Expression [7]
Electrogenic aspartate/glutamate antiporter SLC25A12, mitochondrial (SLC25A12) OTB4YBVT S2512_HUMAN Decreases Expression [7]
Lathosterol oxidase (SC5D) OT41KMW4 SC5D_HUMAN Decreases Expression [7]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Decreases Expression [7]
Fibroblast growth factor 19 (FGF19) OT2DVJWY FGF19_HUMAN Increases Expression [7]
Alcohol dehydrogenase 1C (ADH1C) OTO1DV7F ADH1G_HUMAN Decreases Expression [7]
Glutathione reductase, mitochondrial (GSR) OTM2TUYM GSHR_HUMAN Increases Expression [7]
Alpha-1-antitrypsin (SERPINA1) OTACYW9J A1AT_HUMAN Decreases Expression [7]
Alpha-2-macroglobulin (A2M) OTFTX90K A2MG_HUMAN Decreases Expression [7]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Decreases Expression [7]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Decreases Expression [7]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [7]
GTPase HRas (HRAS) OTWQN0DP RASH_HUMAN Decreases Expression [7]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Decreases Expression [7]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Expression [7]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Decreases Expression [7]
Apolipoprotein A-I (APOA1) OT5THARI APOA1_HUMAN Decreases Expression [7]
Apolipoprotein E (APOE) OTFOWL2H APOE_HUMAN Decreases Expression [7]
Apolipoprotein A-II (APOA2) OTQ3HGTC APOA2_HUMAN Increases Expression [7]
Apolipoprotein C-II (APOC2) OTLINYIQ APOC2_HUMAN Increases Expression [7]
Apolipoprotein C-III (APOC3) OTW3520C APOC3_HUMAN Decreases Expression [7]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [7]
Albumin (ALB) OTVMM513 ALBU_HUMAN Decreases Expression [7]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Decreases Expression [7]
Fructose-bisphosphate aldolase A (ALDOA) OTWRFTIB ALDOA_HUMAN Decreases Expression [7]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Increases Expression [7]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Decreases Expression [7]
Phosphatidylcholine-sterol acyltransferase (LCAT) OTRLMLK0 LCAT_HUMAN Decreases Expression [7]
Thymidine kinase, cytosolic (TK1) OTY5JFM1 KITH_HUMAN Decreases Expression [7]
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) OTBPMIMW G3P_HUMAN Decreases Expression [7]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Expression [7]
Fructose-bisphosphate aldolase B (ALDOB) OT7FR69A ALDOB_HUMAN Decreases Expression [7]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Decreases Expression [7]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Decreases Expression [7]
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Decreases Expression [7]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [7]
Alpha-enolase (ENO1) OTB1KWJS ENOA_HUMAN Decreases Expression [7]
Histone H2B type 1-J (H2BC11) OTGM083T H2B1J_HUMAN Decreases Expression [7]
Protein disulfide-isomerase (P4HB) OTTYNYPF PDIA1_HUMAN Increases Expression [7]
Apolipoprotein(a) (LPA) OTRZLU9F APOA_HUMAN Decreases Expression [7]
Monocyte differentiation antigen CD14 (CD14) OT83GJ47 CD14_HUMAN Decreases Expression [7]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Expression [7]
Steroid 21-hydroxylase (CYP21A2) OTN0UDVP CP21A_HUMAN Decreases Expression [7]
Interleukin-6 receptor subunit alpha (IL6R) OTCQL07Z IL6RA_HUMAN Decreases Expression [7]
Proto-oncogene tyrosine-protein kinase ROS (ROS1) OTDSKUGE ROS1_HUMAN Increases Expression [7]
3-ketoacyl-CoA thiolase, peroxisomal (ACAA1) OTVKRET0 THIK_HUMAN Increases Expression [7]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Decreases Expression [7]
Fructose-1,6-bisphosphatase 1 (FBP1) OTQBANEP F16P1_HUMAN Decreases Expression [7]
Inhibin beta B chain (INHBB) OT2QLD11 INHBB_HUMAN Increases Expression [7]
Fructose-bisphosphate aldolase C (ALDOC) OTEC13I5 ALDOC_HUMAN Increases Expression [7]
Serum amyloid A-1 protein (SAA1) OTO2D8S0 SAA1_HUMAN Increases Expression [7]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Increases Expression [7]
Transforming growth factor beta-3 proprotein (TGFB3) OT2LOUQ1 TGFB3_HUMAN Increases Expression [7]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Expression [7]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases Expression [7]
Hepatic triacylglycerol lipase (LIPC) OTZY5SC9 LIPC_HUMAN Decreases Expression [7]
Pyruvate carboxylase, mitochondrial (PC) OT6O0V51 PYC_HUMAN Decreases Expression [7]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Increases Expression [7]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Decreases Expression [7]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Decreases Expression [7]
Beta-enolase (ENO3) OT3HYKYI ENOB_HUMAN Increases Expression [7]
Farnesyl pyrophosphate synthase (FDPS) OT6CKWV5 FPPS_HUMAN Decreases Expression [7]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 (PFKFB1) OTTHX4NB F261_HUMAN Increases Expression [7]
Protein kinase C alpha type (PRKCA) OT5UWNRD KPCA_HUMAN Increases Expression [7]
Transcription factor JunB (JUNB) OTG2JXV5 JUNB_HUMAN Decreases Expression [7]
Glutathione peroxidase 2 (GPX2) OTXI2NTI GPX2_HUMAN Decreases Expression [7]
Syndecan-1 (SDC1) OTWKRVZC SDC1_HUMAN Increases Expression [7]
Retinoic acid receptor RXR-alpha (RXRA) OTP1TBDM RXRA_HUMAN Decreases Expression [7]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Increases Expression [7]
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) OTDS2EAR TNR1B_HUMAN Increases Expression [7]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Decreases Expression [7]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Increases Expression [7]
Glycerol-3-phosphate dehydrogenase , cytoplasmic (GPD1) OTQW7TMB GPDA_HUMAN Decreases Expression [7]
Glutathione peroxidase 3 (GPX3) OT6PK94R GPX3_HUMAN Increases Expression [7]
Fibroblast growth factor receptor 4 (FGFR4) OTRQERG2 FGFR4_HUMAN Decreases Expression [7]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Increases Expression [7]
Cytochrome P450 3A7 (CYP3A7) OTTCDHHM CP3A7_HUMAN Decreases Expression [7]
Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) OT5BZ1J9 P85A_HUMAN Decreases Expression [7]
Peroxiredoxin-6 (PRDX6) OTS8KC8A PRDX6_HUMAN Decreases Expression [7]
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform (PPP2R1B) OTFIHQGD 2AAB_HUMAN Increases Expression [7]
Glutathione S-transferase theta-1 (GSTT1) OTRFMWBK GSTT1_HUMAN Increases Expression [7]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [7]
RAC-beta serine/threonine-protein kinase (AKT2) OTBB632K AKT2_HUMAN Decreases Expression [7]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Decreases Expression [7]
Glycerol kinase (GK) OTK2YRA0 GLPK_HUMAN Decreases Expression [7]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Decreases Expression [7]
Protein S100-A3 (S100A3) OTVIZJ2R S10A3_HUMAN Decreases Expression [7]
Phosphoenolpyruvate carboxykinase, cytosolic (PCK1) OTNWEJ5Y PCKGC_HUMAN Decreases Expression [7]
Insulin-like growth factor-binding protein complex acid labile subunit (IGFALS) OTTWCZYM ALS_HUMAN Decreases Expression [7]
Phosphoglucomutase-1 (PGM1) OT3VM4JX PGM1_HUMAN Decreases Expression [7]
TGF-beta receptor type-1 (TGFBR1) OT40S1SJ TGFR1_HUMAN Decreases Expression [7]
Sterol regulatory element-binding protein 1 (SREBF1) OTWBRPAI SRBP1_HUMAN Decreases Expression [7]
Interleukin-6 receptor subunit beta (IL6ST) OT1N9C70 IL6RB_HUMAN Decreases Expression [7]
Malate dehydrogenase, cytoplasmic (MDH1) OTJEO4E8 MDHC_HUMAN Increases Expression [7]
Mitogen-activated protein kinase kinase kinase 8 (MAP3K8) OTOZTA1F M3K8_HUMAN Increases Expression [7]
3-ketoacyl-CoA thiolase, mitochondrial (ACAA2) OTGLVWOP THIM_HUMAN Increases Expression [7]
ATP-binding cassette sub-family G member 1 (ABCG1) OT5BG6MK ABCG1_HUMAN Decreases Expression [7]
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3) OTI2OREX MP2K3_HUMAN Decreases Expression [7]
Lanosterol synthase (LSS) OT9W2SFH LSS_HUMAN Decreases Expression [7]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Decreases Expression [7]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A) OTI862QH CPT1A_HUMAN Increases Expression [7]
Interleukin-1 receptor-associated kinase 1 (IRAK1) OT133G8J IRAK1_HUMAN Decreases Expression [7]
Aldo-keto reductase family 1 member D1 (AKR1D1) OTBDJ6RL AK1D1_HUMAN Decreases Expression [7]
Dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6) OTK13JKC MP2K6_HUMAN Decreases Expression [7]
Tricarboxylate transport protein, mitochondrial (SLC25A1) OTIDXQ9F TXTP_HUMAN Decreases Expression [7]
Diphosphomevalonate decarboxylase (MVD) OTGEX4SR MVD1_HUMAN Decreases Expression [7]
Mitogen-activated protein kinase 12 (MAPK12) OTTCKE27 MK12_HUMAN Decreases Expression [7]
Glycogen synthase, liver (GYS2) OTCKIUYR GYS2_HUMAN Increases Expression [7]
Phospholipid transfer protein (PLTP) OTVJJO5Z PLTP_HUMAN Decreases Expression [7]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Decreases Expression [7]
3-keto-steroid reductase/17-beta-hydroxysteroid dehydrogenase 7 (HSD17B7) OTV7VOV3 DHB7_HUMAN Decreases Expression [7]
Transforming growth factor beta-2 proprotein (TGFB2) OTC0TXEP TGFB2_HUMAN Decreases Expression [7]
Ras-related protein R-Ras2 (RRAS2) OT83NCEB RRAS2_HUMAN Increases Expression [7]
Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform (PPP2CB) OT24GMCM PP2AB_HUMAN Increases Expression [7]
Metallothionein-1H (MT1H) OT0MVBM6 MT1H_HUMAN Decreases Expression [7]
Basement membrane-specific heparan sulfate proteoglycan core protein (HSPG2) OT6HTSJT PGBM_HUMAN Decreases Expression [7]
Nuclear factor NF-kappa-B p100 subunit (NFKB2) OTS231V7 NFKB2_HUMAN Decreases Expression [7]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Decreases Expression [7]
Protein kinase C epsilon type (PRKCE) OT7J0P9L KPCE_HUMAN Increases Expression [7]
Sterol 26-hydroxylase, mitochondrial (CYP27A1) OT649C01 CP27A_HUMAN Decreases Expression [7]
DNA-binding protein inhibitor ID-2 (ID2) OT0U1D53 ID2_HUMAN Decreases Expression [7]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Increases Expression [7]
Mevalonate kinase (MVK) OTHJCUKT KIME_HUMAN Decreases Expression [7]
Peroxiredoxin-1 (PRDX1) OTZ3BEC4 PRDX1_HUMAN Decreases Expression [7]
Cytochrome P450 4F3 (CYP4F3) OTYNSQAM CP4F3_HUMAN Decreases Expression [7]
Adenylate cyclase type 1 (ADCY1) OTSLLFZO ADCY1_HUMAN Increases Expression [7]
Sterol regulatory element-binding protein 2 (SREBF2) OTBXUNPL SRBP2_HUMAN Decreases Expression [7]
Dihydropyrimidine dehydrogenase (DPYD) OTWRF2NR DPYD_HUMAN Decreases Expression [7]
TNF receptor-associated factor 2 (TRAF2) OT1MEZZN TRAF2_HUMAN Decreases Expression [7]
Protein AF1q (MLLT11) OTG5RVHC AF1Q_HUMAN Increases Expression [7]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Decreases Expression [7]
FAS-associated death domain protein (FADD) OTV7GFHH FADD_HUMAN Increases Expression [7]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [7]
Isopentenyl-diphosphate Delta-isomerase 1 (IDI1) OTGM06VJ IDI1_HUMAN Decreases Expression [7]
Phosphatidate phosphatase LPIN1 (LPIN1) OTQ75KF2 LPIN1_HUMAN Decreases Expression [7]
Delta(14)-sterol reductase LBR (LBR) OT1HG3HG LBR_HUMAN Decreases Expression [7]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Expression [7]
Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) OTM0A0DY ACOX1_HUMAN Increases Expression [7]
Ribosomal protein S6 kinase alpha-2 (RPS6KA2) OTIOYUSU KS6A2_HUMAN Increases Expression [7]
Transcription elongation factor A protein 2 (TCEA2) OT1OS9TY TCEA2_HUMAN Increases Expression [7]
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 (TAB1) OTPM6F85 TAB1_HUMAN Decreases Expression [7]
Mitogen-activated protein kinase 11 (MAPK11) OT0AS010 MK11_HUMAN Decreases Expression [7]
Methylsterol monooxygenase 1 (MSMO1) OTKV62RZ MSMO1_HUMAN Decreases Expression [7]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Expression [7]
Dual specificity protein phosphatase 6 (DUSP6) OT4H6RKW DUS6_HUMAN Increases Expression [7]
Lanosterol 14-alpha demethylase (CYP51A1) OTAYHG9C CP51A_HUMAN Decreases Expression [7]
Meteorin-like protein (METRNL) OTB0DDL0 METRL_HUMAN Decreases Expression [7]
Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3) OTDMU3GP CR3L3_HUMAN Increases Expression [7]
Single Ig IL-1-related receptor (SIGIRR) OTNC3XFD SIGIR_HUMAN Decreases Expression [7]
Ultra-long-chain fatty acid omega-hydroxylase (CYP4F22) OTMNPZQL CP4FN_HUMAN Decreases Expression [7]
Vitamin D 25-hydroxylase (CYP2R1) OT0L1M1D CP2R1_HUMAN Increases Expression [7]
SUZ domain-containing protein 1 (SZRD1) OTJMEJWT SZRD1_HUMAN Increases Expression [7]
Cytochrome P450 2U1 (CYP2U1) OT6RXLXS CP2U1_HUMAN Increases Expression [7]
Tubulin epsilon and delta complex protein 1 (TEDC1) OT2RIGR7 TEDC1_HUMAN Decreases Expression [7]
ADAMTS-like protein 2 (ADAMTSL2) OTAXNV2U ATL2_HUMAN Decreases Expression [7]
60 kDa lysophospholipase (ASPG) OT5E2EKR LPP60_HUMAN Decreases Expression [7]
Organic solute transporter subunit alpha (SLC51A) OTDJRZ0P OSTA_HUMAN Increases Expression [7]
Organic solute transporter subunit beta (SLC51B) OT4WYPSR OSTB_HUMAN Increases Expression [7]
Na(+)/citrate cotransporter (SLC13A5) OTPH1TA7 S13A5_HUMAN Decreases Expression [7]
Leucine-rich repeat LGI family member 4 (LGI4) OTZGS8BN LGI4_HUMAN Increases Expression [7]
Neuropeptide W (NPW) OTO7MT28 NPW_HUMAN Decreases Expression [7]
Sodium-dependent lysophosphatidylcholine symporter 1 (MFSD2A) OTVG1VG0 NLS1_HUMAN Increases Expression [7]
Mixed lineage kinase domain-like protein (MLKL) OTDSLC81 MLKL_HUMAN Decreases Expression [7]
Scavenger receptor class B member 1 (SCARB1) OTAE1UA1 SCRB1_HUMAN Increases Expression [7]
Phosphatidate phosphatase LPIN2 (LPIN2) OTRRTMXX LPIN2_HUMAN Decreases Expression [7]
Caspase-10 (CASP10) OTE6J88E CASPA_HUMAN Increases Expression [7]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Decreases Expression [7]
Cyclic AMP-responsive element-binding protein 3-like protein 1 (CREB3L1) OT2JHIHM CR3L1_HUMAN Decreases Expression [7]
Diacylglycerol O-acyltransferase 2 (DGAT2) OTE5PDD0 DGAT2_HUMAN Decreases Expression [7]
Leukocyte receptor cluster member 8 (LENG8) OT6B5K2T LENG8_HUMAN Increases Expression [7]
Cytochrome P450 2S1 (CYP2S1) OTKHX4RF CP2S1_HUMAN Decreases Expression [7]
Peroxisomal acyl-coenzyme A oxidase 2 (ACOX2) OT3VH359 ACOX2_HUMAN Increases Expression [7]
Mitogen-activated protein kinase kinase kinase 14 (MAP3K14) OTT3DOOL M3K14_HUMAN Decreases Expression [7]
Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) OTQR6ENW M3K5_HUMAN Decreases Expression [7]
Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial (ECSIT) OTJX1YC7 ECSIT_HUMAN Decreases Expression [7]
Receptor-transporting protein 3 (RTP3) OTZUDJ6Q RTP3_HUMAN Increases Expression [7]
Very long chain fatty acid elongase 1 (ELOVL1) OTIDTQ8R ELOV1_HUMAN Increases Expression [7]
Protein amnionless (AMN) OTS1TJXG AMNLS_HUMAN Decreases Expression [7]
Forkhead box protein P3 (FOXP3) OTA9Z9OC FOXP3_HUMAN Increases Expression [7]
3 beta-hydroxysteroid dehydrogenase type 7 (HSD3B7) OT2Y9IW4 3BHS7_HUMAN Decreases Expression [7]
Lck-interacting transmembrane adapter 1 (LIME1) OTJWUQSK LIME1_HUMAN Decreases Expression [7]
Very long chain fatty acid elongase 6 (ELOVL6) OTB26UJJ ELOV6_HUMAN Decreases Expression [7]
Cytochrome P450 3A43 (CYP3A43) OTMXADGA CP343_HUMAN Decreases Expression [7]
Cytochrome P450 4F11 (CYP4F11) OTHZ2GG2 CP4FB_HUMAN Decreases Expression [7]
Glycerol-3-phosphate acyltransferase 1, mitochondrial (GPAM) OTR1XD9B GPAT1_HUMAN Decreases Expression [7]
Cytochrome P450 4F12 (CYP4F12) OTIUY7E6 CP4FC_HUMAN Decreases Expression [7]
Solute carrier organic anion transporter family member 1B3 (SLCO1B3) OTOM3BUH SO1B3_HUMAN Increases Expression [7]
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (AGPAT5) OTNY3VMD PLCE_HUMAN Decreases Expression [7]
Very long chain fatty acid elongase 2 (ELOVL2) OTDAF6U3 ELOV2_HUMAN Increases Expression [7]
24-hydroxycholesterol 7-alpha-hydroxylase (CYP39A1) OTBAJT4I CP39A_HUMAN Decreases Expression [7]
Very-long-chain enoyl-CoA reductase (TECR) OT2NT4MV TECR_HUMAN Decreases Expression [7]
C5a anaphylatoxin chemotactic receptor 2 (C5AR2) OTP1Q82J C5AR2_HUMAN Decreases Expression [7]
7-dehydrocholesterol reductase (DHCR7) OTLILBUI DHCR7_HUMAN Increases Expression [7]
DnaJ homolog subfamily B member 11 (DNAJB11) OTDDK2SY DJB11_HUMAN Increases Expression [7]
Mitochondrial dicarboxylate carrier (SLC25A10) OTT8647H DIC_HUMAN Decreases Expression [7]
Cysteine-rich C-terminal protein 1 (CRCT1) OTPYME8V CRCT1_HUMAN Decreases Expression [7]
Fetuin-B (FETUB) OT7V07NI FETUB_HUMAN Increases Expression [7]
Polypyrimidine tract-binding protein 2 (PTBP2) OTF4S7NE PTBP2_HUMAN Decreases Expression [7]
Long-chain-fatty-acid--CoA ligase 6 (ACSL6) OT0TT8P8 ACSL6_HUMAN Increases Expression [7]
Long-chain-fatty-acid--CoA ligase 5 (ACSL5) OT3L9XO3 ACSL5_HUMAN Increases Expression [7]
Myocardin-related transcription factor B (MRTFB) OT9OXGS9 MRTFB_HUMAN Decreases Expression [7]
Carbonic anhydrase 14 (CA14) OT1TRKFN CAH14_HUMAN Increases Expression [7]
Transcription factor MafF (MAFF) OT9B7MX0 MAFF_HUMAN Increases Expression [7]
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase (CYP8B1) OTRI4UR1 CP8B1_HUMAN Increases Expression [7]
Protein phosphatase 1 regulatory subunit 3C (PPP1R3C) OTEU05TX PPR3C_HUMAN Decreases Expression [7]
Long-chain fatty acid transport protein 5 (SLC27A5) OT4OK511 S27A5_HUMAN Decreases Expression [7]
Acyl-coenzyme A thioesterase 9, mitochondrial (ACOT9) OTBOQE6N ACOT9_HUMAN Increases Expression [7]
Chloride intracellular channel protein 4 (CLIC4) OT6KTPKD CLIC4_HUMAN Increases Expression [7]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) OTNEN8QK SO1B1_HUMAN Decreases Expression [7]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Increases Expression [10]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Secretion [11]
Cytochrome P450 7A1 (CYP7A1) OT8Z5KLD CP7A1_HUMAN Decreases Expression [10]
Hepatic sodium/bile acid cotransporter (SLC10A1) OTUJVMCL NTCP_HUMAN Decreases Expression [10]
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Increases Expression [10]
Protein arginine N-methyltransferase 1 (PRMT1) OTN8GTXW ANM1_HUMAN Increases Activity [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 230 DOT(s)
Indication(s) of Bezafibrate
Disease Entry ICD 11 Status REF
Hypercholesterolaemia 5C80.0 Approved [4]
Hyperlipidaemia 5C80 Approved [5]
Hyperlipidemia 5C80.Z Approved [6]
Bezafibrate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Peroxisome proliferator-activated receptor alpha (PPARA) TTJ584C PPARA_HUMAN Agonist [14]
------------------------------------------------------------------------------------
Bezafibrate Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [15]
------------------------------------------------------------------------------------
Bezafibrate Interacts with 63 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Increases Activity [16]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL) OTG7J4BP PPBT_HUMAN Decreases Activity [17]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Increases Expression [18]
Cytochrome b-245 light chain (CYBA) OT16N9ZO CY24A_HUMAN Decreases Expression [18]
Peroxisome proliferator-activated receptor delta (PPARD) OTI4WTOP PPARD_HUMAN Increases Expression [18]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Expression [19]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [20]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Increases Expression [20]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Decreases Expression [21]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Expression [22]
Bifunctional epoxide hydrolase 2 (EPHX2) OTPTRCNW HYES_HUMAN Affects Expression [22]
Cytochrome P450 2J2 (CYP2J2) OTJBTEH8 CP2J2_HUMAN Affects Expression [22]
Protein SCO2 homolog, mitochondrial (SCO2) OTJQQDRS SCO2_HUMAN Increases Activity [23]
Nephrin (NPHS1) OT21JD3P NPHN_HUMAN Increases Expression [24]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Expression [25]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Increases Expression [26]
Insulin (INS) OTZ85PDU INS_HUMAN Decreases Expression [27]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Response To Substance [28]
Apolipoprotein A-I (APOA1) OT5THARI APOA1_HUMAN Decreases Expression [29]
Apolipoprotein E (APOE) OTFOWL2H APOE_HUMAN Increases Expression [30]
Apolipoprotein A-II (APOA2) OTQ3HGTC APOA2_HUMAN Increases Expression [31]
Apolipoprotein C-III (APOC3) OTW3520C APOC3_HUMAN Decreases Expression [32]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [33]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Decreases Expression [34]
Insulin-like growth factor I (IGF1) OTIIZR61 IGF1_HUMAN Decreases Expression [35]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Increases Expression [36]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Decreases Expression [37]
Fatty acid-binding protein, heart (FABP3) OT562DA1 FABPH_HUMAN Decreases Expression [38]
Lipoprotein lipase (LPL) OTTW0267 LIPL_HUMAN Increases Activity [32]
Fatty acid-binding protein, liver (FABP1) OTR34ETM FABPL_HUMAN Decreases Expression [38]
Choriogonadotropin subunit beta 3 (CGB3) OTVM2SU3 CGB3_HUMAN Decreases Secretion [38]
Osteopontin (SPP1) OTJGC23Y OSTP_HUMAN Decreases Expression [39]
Hepatic triacylglycerol lipase (LIPC) OTZY5SC9 LIPC_HUMAN Increases Activity [40]
Cholesteryl ester transfer protein (CETP) OTAGPPOE CETP_HUMAN Decreases Activity [41]
Fatty acid-binding protein, adipocyte (FABP4) OT3DKFOU FABP4_HUMAN Increases Expression [42]
Platelet glycoprotein 4 (CD36) OT5CZWKY CD36_HUMAN Increases Expression [42]
Retinoic acid receptor RXR-alpha (RXRA) OTP1TBDM RXRA_HUMAN Affects Binding [43]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Increases Expression [25]
Cytochrome P450 7A1 (CYP7A1) OT8Z5KLD CP7A1_HUMAN Decreases Expression [44]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Increases Expression [45]
Retinoic acid receptor RXR-beta (RXRB) OTNPDXG2 RXRB_HUMAN Affects Binding [43]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Activity [46]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Increases Expression [47]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Decreases Expression [38]
Leptin (LEP) OT5Q7ODW LEP_HUMAN Decreases Expression [48]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Affects Expression [49]
Retinoic acid receptor RXR-gamma (RXRG) OT254B09 RXRG_HUMAN Affects Binding [43]
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADVL) OT50L4XB ACADV_HUMAN Increases Expression [50]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A) OTI862QH CPT1A_HUMAN Increases Expression [47]
Aldehyde dehydrogenase family 3 member A2 (ALDH3A2) OT714BUO AL3A2_HUMAN Increases Expression [51]
Oxysterols receptor LXR-beta (NR1H2) OT4APA60 NR1H2_HUMAN Increases Expression [26]
Phospholipid transfer protein (PLTP) OTVJJO5Z PLTP_HUMAN Decreases Activity [41]
Sterol regulatory element-binding protein 2 (SREBF2) OTBXUNPL SRBP2_HUMAN Increases Expression [44]
Oxysterols receptor LXR-alpha (NR1H3) OT54YZ9I NR1H3_HUMAN Increases Expression [26]
Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) OTM0A0DY ACOX1_HUMAN Increases Expression [52]
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Increases Expression [53]
kinase isozyme 4, mitochondrial (PDK4) OTCMHMBZ PDK4_HUMAN Increases Expression [54]
Proprotein convertase subtilisin/kexin type 9 (PCSK9) OTI0DU9Y PCSK9_HUMAN Increases Expression [53]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Increases Expression [25]
Achaete-scute homolog 2 (ASCL2) OT3D62WB ASCL2_HUMAN Decreases Expression [38]
ATP-binding cassette sub-family G member 5 (ABCG5) OT1OMY93 ABCG5_HUMAN Increases Expression [44]
Fibroblast growth factor 21 (FGF21) OT3RXVRD FGF21_HUMAN Increases Expression [55]
ATP-binding cassette sub-family C member 4 (ABCC4) OTO27PAL MRP4_HUMAN Increases Transport [56]
------------------------------------------------------------------------------------
⏷ Show the Full List of 63 DOT(s)

References

1 ClinicalTrials.gov (NCT05239468) Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
2 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
3 Nuclear receptors and lipid physiology: opening the X-files. Science. 2001 Nov 30;294(5548):1866-70.
4 Simvastatin and bezafibrate: effects on serum lipoproteins and lecithin: cholesterol acyltransferase activity in familial hypercholesterolaemia. Eur J Clin Pharmacol. 1988;35(6):579-83.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2668).
6 Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments. Int J Mol Sci. 2023 Sep 11;24(18):13942.
7 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
8 UGT-dependent regioselective glucuronidation of ursodeoxycholic acid and obeticholic acid and selective transport of the consequent acyl glucuronides by OATP1B1 and 1B3. Chem Biol Interact. 2019 Sep 1;310:108745. doi: 10.1016/j.cbi.2019.108745. Epub 2019 Jul 9.
9 Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J Biol Chem. 1994 Jul 29;269(30):19375-9.
10 The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol. 2005 Aug;68(2):551-8. doi: 10.1124/mol.105.012104. Epub 2005 May 23.
11 Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011 Apr;60(4):463-72. doi: 10.1136/gut.2010.212159. Epub 2011 Jan 17.
12 Changes in matrix proteoglycans induced by insulin and fatty acids in hepatic cells may contribute to dyslipidemia of insulin resistance. Diabetes. 2001 Sep;50(9):2126-32. doi: 10.2337/diabetes.50.9.2126.
13 Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways. Chem Res Toxicol. 2007 Oct;20(10):1520-7. doi: 10.1021/tx700188x. Epub 2007 Sep 20.
14 Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
15 Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
16 Effects of Bezafibrate on Hepatic Cholesterol Metabolism Eur J Clin Pharmacol. 1991;40 Suppl 1:S33-6.
17 The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism. 1993 Jul;42(7):839-42.
18 The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001 Jan;50(1):3-11.
19 Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
20 CYP4A11 is repressed by retinoic acid in human liver cells. FEBS Lett. 2006 Jun 12;580(14):3361-7.
21 Bisphenol A downregulates CYP19 transcription in JEG-3 cells. Toxicol Lett. 2009 Sep 28;189(3):248-52.
22 Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner. Toxicol Appl Pharmacol. 2018 Sep 15;355:156-163.
23 Copper and bezafibrate cooperate to rescue cytochrome c oxidase deficiency in cells of patients with SCO2 mutations. Orphanet J Rare Dis. 2012 Apr 19;7:21. doi: 10.1186/1750-1172-7-21.
24 PPARalpha activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. Biochem Biophys Res Commun. 2005 Dec 30;338(4):1818-24. doi: 10.1016/j.bbrc.2005.10.158. Epub 2005 Nov 2.
25 Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4. J Lipid Res. 2004 Oct;45(10):1813-25. doi: 10.1194/jlr.M400132-JLR200. Epub 2004 Jul 16.
26 On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis. 2009 Aug;205(2):413-9. doi: 10.1016/j.atherosclerosis.2009.01.008. Epub 2009 Jan 19.
27 Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care. 1990 Aug;13(8):855-63. doi: 10.2337/diacare.13.8.855.
28 Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs. Int Immunopharmacol. 2003 Feb;3(2):225-32. doi: 10.1016/S1567-5769(02)00275-8.
29 Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994 Dec 9;269(49):31012-8.
30 Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate. Am J Med. 1994 Jun 6;96(6A):55S-63S. doi: 10.1016/0002-9343(94)90233-x.
31 Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients. Arzneimittelforschung. 1994 Nov;44(11):1217-22.
32 The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding. Atherosclerosis. 2000 Dec;153(2):363-71. doi: 10.1016/s0021-9150(00)00409-3.
33 Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med. 2002 Mar;112(4):275-80. doi: 10.1016/s0002-9343(01)01123-8.
34 Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis. Nephrol Dial Transplant. 1992;7(7):623-6. doi: 10.1093/ndt/7.7.623.
35 Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol. 2000 Mar 1;35(3):647-54. doi: 10.1016/s0735-1097(99)00591-4.
36 Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. Arterioscler Thromb Vasc Biol. 1999 Jun;19(6):1577-81. doi: 10.1161/01.atv.19.6.1577.
37 Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. J Hypertens. 2001 Apr;19(4):749-55. doi: 10.1097/00004872-200104000-00012.
38 Expression of cFABP and PPAR in trophoblast cells: effect of PPAR ligands on linoleic acid uptake and differentiation. Biochim Biophys Acta. 2005 Feb 21;1687(1-3):181-94. doi: 10.1016/j.bbalip.2004.11.017.
39 PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Diabetes. 2007 Jun;56(6):1662-70. doi: 10.2337/db06-1177. Epub 2007 Mar 14.
40 Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia. Eur J Clin Invest. 1986 Feb;16(1):61-8. doi: 10.1111/j.1365-2362.1986.tb01309.x.
41 Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. J Lipid Res. 2003 Aug;44(8):1462-9. doi: 10.1194/jlr.M300008-JLR200. Epub 2003 May 16.
42 Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003 May;52(5):652-7. doi: 10.1053/meta.2003.50100.
43 Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor , , subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11.
44 Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur J Clin Pharmacol. 2004 Feb;59(12):855-61. doi: 10.1007/s00228-003-0704-1. Epub 2003 Dec 18.
45 Bezafibrate upregulates carnitine palmitoyltransferase II expression and promotes mitochondrial energy crisis dissipation in fibroblasts of patients with influenza-associated encephalopathy. Mol Genet Metab. 2011 Nov;104(3):265-72. doi: 10.1016/j.ymgme.2011.07.009. Epub 2011 Jul 20.
46 Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2. Leukemia. 2009 Feb;23(2):292-304. doi: 10.1038/leu.2008.283. Epub 2008 Oct 16.
47 Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice. Chem Biol Interact. 2009 Oct 30;181(3):309-15. doi: 10.1016/j.cbi.2009.08.003. Epub 2009 Aug 12.
48 Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism. 2000 Mar;49(3):331-4. doi: 10.1016/s0026-0495(00)90176-8.
49 Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol. 2004 Apr 7;43(7):1188-94. doi: 10.1016/j.jacc.2003.10.046.
50 Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Am J Hum Genet. 2007 Dec;81(6):1133-43. doi: 10.1086/522375. Epub 2007 Oct 29.
51 Bezafibrate induces FALDH in human fibroblasts; implications for Sj?gren-Larsson syndrome. Mol Genet Metab. 2006 Sep-Oct;89(1-2):111-5. doi: 10.1016/j.ymgme.2006.05.009. Epub 2006 Jul 11.
52 Activation of peroxisome proliferator-activated receptor- (PPAR) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes. Biochem Biophys Res Commun. 2011 Jun 24;410(1):1-6. doi: 10.1016/j.bbrc.2011.05.057. Epub 2011 May 25.
53 Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study. Atherosclerosis. 2011 Jul;217(1):165-70. doi: 10.1016/j.atherosclerosis.2011.02.012. Epub 2011 Feb 22.
54 Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling. Toxicol In Vitro. 2010 Feb;24(1):154-9. doi: 10.1016/j.tiv.2009.08.001. Epub 2009 Aug 13.
55 Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes. 2012 Apr;61(4):797-806. doi: 10.2337/db11-0846. Epub 2012 Feb 14.
56 Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.